Microba Life Sciences Ltd
ASX:MAP
Microba Life Sciences Ltd
Microba Life Sciences is a precision microbiome science company powering medical innovation to transform human health. The company is headquartered in Brisbane, Queensland. The company went IPO on 2022-04-05. The firm specializes in the analysis of gut microbiome and promotes development in pathology services, therapeutics and diagnostics based on the microbiome. The firm's flagship product is the Microba Insight, a sampling kit that allows the public to analyze personal gut microbiome. Its discovery platform uses human data and informatic approaches to connect microbial genotype to human phenotype. The company also offers support solutions to researchers.
Microba Life Sciences is a precision microbiome science company powering medical innovation to transform human health. The company is headquartered in Brisbane, Queensland. The company went IPO on 2022-04-05. The firm specializes in the analysis of gut microbiome and promotes development in pathology services, therapeutics and diagnostics based on the microbiome. The firm's flagship product is the Microba Insight, a sampling kit that allows the public to analyze personal gut microbiome. Its discovery platform uses human data and informatic approaches to connect microbial genotype to human phenotype. The company also offers support solutions to researchers.
Core Test Growth: Core test volumes rose 90% year-on-year, reaching an annualized run rate of over 21,300, with the company on track to exceed 24,000 for the financial year.
Revenue Transition: Microbiome Explorer now makes up 55% of total revenue, fully replacing legacy product revenues that were strategically discontinued.
Cost Management: Net operating cash flows improved as cost reductions implemented in Q2 delivered a full quarter of benefit.
AI Deployments: AI has been implemented across the business, including customer support and software engineering, driving measurable efficiencies.
U.K. & Australia Expansion: Clinical adoption is expanding in both Australia and the U.K., with U.K. uptake 33% ahead of the Australian pace at the same time post-launch.
Supplements Business: U.K. supplements focus shifted to higher-margin Invivo-branded products, delivering a record quarter and 110% year-on-year volume growth for the leading supplement.
Therapeutics Pipeline: Recent sector clinical trial successes are energizing partnering discussions for Microba's therapeutic assets, with potential deals expected to have a material impact on valuation.
Regional Breakeven: The company remains on track to achieve regional breakeven in Australia and the U.K. during FY '26.
